Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management.
The DOI matches its Crossref record.
Abstract
PURPOSE: To determine whether bone scan, magnetic resonance imaging (MRI), or somatostatin receptor scintigraphy (SRS) is best for identifying bone metastases in patients with gastrinomas, as well as their frequency and location, whether their detection affects management, and what patient subgroups should be examined. MATERIALS AND METHODS: One hundred fifteen patients with gastrinoma were prospectively studied. Patients were examined yearly and those with liver metastases were reexamined every 3 months. Based on clinical history, histology, growth pattern, and development of new bone lesions, possible bone metastases were classified as to whether they were or were not bone metastases. Imaging results were correlated at different times in the disease course and with disease extent. RESULTS: Bone scan was positive in 52 patients, MRI in seven, and SRS in six. Eight patients (7%) were determined to have bone metastases and MRI was correctly positive in seven, SRS in six, and bone scan in five. SRS or MRI was positive in all patients with bone metastases. Bone scan had significantly lower specificity and sensitivity, and a higher rate (P < .02) of false-negative results than MRI or SRS. Bone metastases occurred in 31% of patients with liver metastases and 0% with only lymph node metastases. The initial bone metastases were in the spine or sacrum (75%) followed in descending order by the pelvis or sacroiliac joints (38%), scapula or shoulder, and ribs. In all cases, detection of bone metastases changed the management. CONCLUSION: SRS and MRI, because of high sensitivity and specificity, are recommended over bone scanning to screen for bone metastases in patients with gastrinomas. However, because bone metastases can occur initially outside the axial skeleton, SRS is the recommended initial localization method of choice. Bone metastases occur in 7% of all patients and 31% of patients with liver metastases, only occur in patients with liver metastases, are usually in the axial skeleton initially, and their detection changes management in all cases. Patients with pancreatic endocrine tumors with liver metastases should undergo SRS every 6 months to 1 year to detect bone metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
Rindi, G., Klöppel, G., Alhman, H., Caplin, M., Couvelard, A., de Herder, W. W., Erikssson, B., Falchetti, A., Falconi, M., Komminoth, P., et al. (2006) · Virchows Archiv · doi:10.1007/s00428-006-0250-1 · Cited by 1,547
Rindi, G., Klöppel, G., Couvelard, A., Komminoth, P., Körner, M., Lopes, J. M., McNicol, A.-M., Nilsson, O., Perren, A., Scarpa, A., et al. (2007) · Virchows Archiv · doi:10.1007/s00428-007-0452-1 · Cited by 955
Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors
Metz, D. C., & Jensen, R. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.047 · Cited by 816
Self-citationJensen, R. T., Cadiot, G., Brandi, M. L., de Herder, W. W., Kaltsas, G., Komminoth, P., Scoazec, J.-Y., Salazar, R., Sauvanet, A., & Kianmanesh, R. (2012) · Neuroendocrinology · doi:10.1159/000335591 · Cited by 622
Self-citationNANETS Treatment Guidelines: Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas
Kulke, M. H., Anthony, L. B., Bushnell, D. L., de Herder, W. W., Goldsmith, S. J., Klimstra, D. S., Marx, S. J., Pasieka, J. L., Pommier, R. F., Yao, J. C., et al. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb168 · Cited by 574
Self-citationJensen, R. T., Berna, M. J., Bingham, D. B., & Norton, J. A. (2008) · Cancer · doi:10.1002/cncr.23648 · Cited by 488
Self-citationDiagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy
Yang, H.-L., Liu, T., Wang, X.-M., Xu, Y., & Deng, S.-M. (2011) · European Radiology · doi:10.1007/s00330-011-2221-4 · Cited by 374
Yu, F., Venzon, D. J., Serrano, J., Goebel, S. U., Doppman, J. L., Gibril, F., & Jensen, R. T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.615 · Cited by 341
Self-citationENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms
Delle Fave, G., Kwekkeboom, D. J., Van Cutsem, E., Rindi, G., Kos-Kudla, B., Knigge, U., Sasano, H., Tomassetti, P., Salazar, R., & Ruszniewski, P. (2012) · Neuroendocrinology · doi:10.1159/000335595 · Cited by 327
Gibril, F., Schumann, M., Pace, A., & Jensen, R. T. (2004) · Medicine · doi:10.1097/01.md.0000112297.72510.32 · Cited by 313
Self-citationWild, D., Schmitt, J. S., Ginj, M., Mäcke, H. R., Bernard, B. F., Krenning, E., de Jong, M., Wenger, S., & Reubi, J.-C. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1255-5 · Cited by 310
NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor
Vinik, A. I., Woltering, E. A., Warner, R. R. P., Caplin, M., O'Dorisio, T. M., Wiseman, G. A., Coppola, D., & Go, V. L. W. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebaffd · Cited by 287
Gastrinoma (Duodenal and Pancreatic)
Jensen, R. T., Niederle, B., Mitry, E., Ramage, J. K., Steinmüller, T., Lewington, V., Scarpa, A., Sundin, A., Perren, A., Gross, D., et al. (2006) · Neuroendocrinology · doi:10.1159/000098009 · Cited by 284
Self-citationSchirrmeister, H., Guhlmann, A., Kotzerke, J., Santjohanser, C., Kühn, T., Kreienberg, R., Messer, P., Nüssle, K., Elsner, K., Glatting, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2381 · Cited by 283
Shojamanesh, H., Gibril, F., Louie, A., Ojeaburu, J. V., Bashir, S., Abou‐Saif, A., & Jensen, R. T. (2002) · Cancer · doi:10.1002/cncr.10195 · Cited by 215
Self-citationNuclear medicine in the detection and management of pancreatic islet-cell tumours.
Virgolini, I., Traub-Weidinger, T., & Decristoforo, C. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.09.001 · Cited by 93
Metadata
- Authors
- Gibril, F., Doppman, J. L., Reynolds, J. C., Chen, C. C., Sutliff, V. E., Yu, F., Serrano, J., Venzon, D. J., & Jensen, R. T.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-03
- Volume
- 16
- Issue
- 3
- Pages
- 1040-1053
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1856543148
- Cited by
- 143
- References
- 0
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.